We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Presentation event of the new histotripsy device in Vall d'Hebron.
The team will investigate, in animal models, the benefits of histotripsy, a technique that allows tumors to be destroyed without incision or heat, and hopes to minimize the risks and enhance the efficacy of immunotherapy.
Vall d'Hebron Barcelona Hospital Campus advances in oncology research thanks to the recent incorporation of a new histotripsy device manufactured exclusively for our institution from Virginia Tech University. This innovative device, which will be tested on animal models* as part of basic research, uses high-intensity focused ultrasound to destroy tissues and tumors mechanically without the need for radiation or skin incisions. The device, officially presented at an event held on June 6, was acquired thanks to a grant from Cris Contra el Cáncer, under the program "Vivir es urgente", in memory of the musician Pau Donés.
The new equipment has been manufactured by Virginia Tech University especially for Vall d'Hebron by bioengineer Eli Vlaisavljevich, a pioneer in the development of histotripsy. This technology will be tested at Vall d'Hebron in the framework of the research line on high intensity focused ultrasound (FUSMED), led by Dr. Xavier Serres i Créixams, interventional radiologist of the Radiology Service of Vall d'Hebron Hospital and principal investigator of the Molecular Medical Imaging group of VHIR.
Histotripsy is a technique that uses ultrasound to achieve tumor removal. Unlike other techniques that use ultrasound for the same purpose, histotripsy produces a mechanical trituration of the tumors without generating heat.
In addition to achieving tumor destruction at the site of therapy, the fact that the tumor is destroyed without generating heat prevents proteins from denaturing and allows a more precise and potent immune response to be generated. "Histotripsy not only destroys the primary tumor, but could also help the immune system to identify and attack metastases in other parts of the body that have not been directly treated with ultrasound", explains Dr. Xavier Serres.
Previously, Vall d'Hebron had already participated in the Theresa and Hope4Liver studies, together with the company Histosonics. "A team of expert radiologists from Vall d'Hebron carried out the first validation studies of the histotripsy technique in humans worldwide, and this has allowed the commercialization of a histotripsy device for humans in the United States. Now we are going to contribute to the development of the technique in animal models, to improve its future applications", explains Dr. Manel Escobar, Clinical Director of Diagnostic Imaging and Nuclear Medicine at Vall d'Hebron. "With this new device we will also explore new ways to combine histotripsy with immunotherapy to increase the efficacy of cancer treatments. Advancing in the knowledge of the benefits of hystotripsy is key to improving the survival and quality of life of patients", assures Dr. Serres.
"Histotripsy is a breakthrough in the multidisciplinary treatment of advanced or metastatic tumors", says Dr. Josep Tabernero, head of the Medical Oncology Department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology (VHIO). "The incorporation of this pioneering technology in the field of preclinical research at the Vall d'Hebron Campus opens the door to continue advancing in the comprehensive treatment of cancer patients, always offering them the best technology and the best treatment possibilities".
*Institutional Declaration on the Use of Animals in Research
Radiodiagnosis (IDI), General Hospital
Director, Vall d’Hebron Institute of Oncology
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.